Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease.

Ma QL, Teng E, Zuo X, Jones M, Teter B, Zhao EY, Zhu C, Bilousova T, Gylys KH, Apostolova LG, LaDu MJ, Hossain MA, Frautschy SA, Cole GM.

Neurobiol Dis. 2018 Jun;114:120-128. doi: 10.1016/j.nbd.2018.02.014. Epub 2018 Mar 6.

PMID:
29501530
2.

Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.

Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, Kile SJ, Blanco A, Fuchs DT, Ashfaq A, Frautschy S, Cole GM, Miller CA, Hinton DR, Verdooner SR, Black KL, Koronyo-Hamaoui M.

JCI Insight. 2017 Aug 17;2(16). pii: 93621. doi: 10.1172/jci.insight.93621. [Epub ahead of print]

3.

Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain.

Teter B, LaDu MJ, Sullivan PM, Frautschy SA, Cole GM.

Neuroreport. 2016 Aug 3;27(11):791-5. doi: 10.1097/WNR.0000000000000608.

4.

Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases.

Bilousova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C, Hayden EY, Teplow DB, Glabe C, Albay R 3rd, Cole GM, Teng E, Gylys KH.

Am J Pathol. 2016 Jan;186(1):185-98. doi: 10.1016/j.ajpath.2015.09.018.

5.

Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.

Teng E, Taylor K, Bilousova T, Weiland D, Pham T, Zuo X, Yang F, Chen PP, Glabe CG, Takacs A, Hoffman DR, Frautschy SA, Cole GM.

Neurobiol Dis. 2015 Oct;82:552-560. doi: 10.1016/j.nbd.2015.09.002. Epub 2015 Sep 12.

7.

Plasma BDNF levels associate with Pittsburgh compound B binding in the brain.

Hwang KS, Lazaris AS, Eastman JA, Teng E, Thompson PM, Gylys KH, Cole GM, Apostolova LG; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (Amst). 2015 Jun 1;1(2):187-193.

8.

Clinical development of curcumin in neurodegenerative disease.

Hu S, Maiti P, Ma Q, Zuo X, Jones MR, Cole GM, Frautschy SA.

Expert Rev Neurother. 2015 Jun;15(6):629-37. doi: 10.1586/14737175.2015.1044981. Review.

PMID:
26035622
9.

Neuroinflammation in Alzheimer's disease.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP.

Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. Review.

10.

Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort.

Teng E, Chow N, Hwang KS, Thompson PM, Gylys KH, Cole GM, Jack CR Jr, Shaw LM, Trojanowski JQ, Soares HD, Weiner MW, Apostolova LG; Alzheimer’s Disease Neuroimaging Initiative.

Dement Geriatr Cogn Disord. 2015;39(3-4):154-66. doi: 10.1159/000368982. Epub 2014 Dec 24.

11.

Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease.

Bilousova T, Taylor K, Emirzian A, Gylys R, Frautschy SA, Cole GM, Teng E.

Neurobiol Dis. 2015 Feb;74:32-40. doi: 10.1016/j.nbd.2014.11.006. Epub 2014 Nov 13.

12.

Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging.

Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Kiosea NC, Nazari S, Chen PP, Nothias F, Chan P, Teng E, Frautschy SA, Cole GM.

J Neurosci. 2014 May 21;34(21):7124-36. doi: 10.1523/JNEUROSCI.3439-13.2014.

13.

Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice.

Ong QR, Chan ES, Lim ML, Cole GM, Wong BS.

Sci Rep. 2014 Jan 17;4:3754. doi: 10.1038/srep03754.

14.

Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.

Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA.

J Biol Chem. 2013 Feb 8;288(6):4056-65. doi: 10.1074/jbc.M112.393751. Epub 2012 Dec 21.

15.

PAK in Alzheimer disease, Huntington disease and X-linked mental retardation.

Ma QL, Yang F, Frautschy SA, Cole GM.

Cell Logist. 2012 Apr 1;2(2):117-125.

16.

C-terminal turn stability determines assembly differences between Aβ40 and Aβ42.

Roychaudhuri R, Yang M, Deshpande A, Cole GM, Frautschy S, Lomakin A, Benedek GB, Teplow DB.

J Mol Biol. 2013 Jan 23;425(2):292-308. doi: 10.1016/j.jmb.2012.11.006. Epub 2012 Nov 12.

17.

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.

Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM.

Alzheimers Res Ther. 2012 Oct 29;4(5):43. doi: 10.1186/alzrt146. eCollection 2012.

18.

Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM.

Arch Neurol. 2012 Jun;69(6):757-64. doi: 10.1001/archneurol.2012.277.

19.

Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.

Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, Cummings JL, Cole GM.

Dement Geriatr Cogn Disord. 2012;33(1):1-5. doi: 10.1159/000335729. Epub 2012 Feb 13.

20.

Isolation of synaptic terminals from Alzheimer's disease cortex.

Sokolow S, Henkins KM, Williams IA, Vinters HV, Schmid I, Cole GM, Gylys KH.

Cytometry A. 2012 Mar;81(3):248-54. doi: 10.1002/cyto.a.22009. Epub 2011 Dec 28.

21.

Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex.

Arold S, Sullivan P, Bilousova T, Teng E, Miller CA, Poon WW, Vinters HV, Cornwell LB, Saing T, Cole GM, Gylys KH.

Acta Neuropathol. 2012 Jan;123(1):39-52. doi: 10.1007/s00401-011-0892-1. Epub 2011 Oct 22.

22.

AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly.

Sokolow S, Henkins KM, Bilousova T, Miller CA, Vinters HV, Poon W, Cole GM, Gylys KH.

Neurobiol Aging. 2012 Aug;33(8):1545-55. doi: 10.1016/j.neurobiolaging.2011.05.011. Epub 2011 Jul 7.

23.

[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.

Teng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, Chen PP, Cole GB, Jones MR, Huang SC, Flood DG, Trusko SP, Small GW, Cole GM, Barrio JR.

Neurobiol Dis. 2011 Sep;43(3):565-75. doi: 10.1016/j.nbd.2011.05.003. Epub 2011 May 13.

24.

What was lost in translation in the DHA trial is whom you should intend to treat.

Frautschy SA, Cole GM.

Alzheimers Res Ther. 2011 Jan 20;3(1):2. doi: 10.1186/alzrt61.

25.

Dietary fatty acids and the aging brain.

Cole GM, Ma QL, Frautschy SA.

Nutr Rev. 2010 Dec;68 Suppl 2:S102-11. doi: 10.1111/j.1753-4887.2010.00345.x. Review.

26.

Why pleiotropic interventions are needed for Alzheimer's disease.

Frautschy SA, Cole GM.

Mol Neurobiol. 2010 Jun;41(2-3):392-409. doi: 10.1007/s12035-010-8137-1. Epub 2010 May 2. Review.

27.

Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Cole GM, Frautschy SA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-8. Review.

28.

DHA may prevent age-related dementia.

Cole GM, Frautschy SA.

J Nutr. 2010 Apr;140(4):869-74. doi: 10.3945/jn.109.113910. Epub 2010 Feb 24. Review.

29.

Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.

Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM.

J Neurosci. 2009 Jul 15;29(28):9078-89. doi: 10.1523/JNEUROSCI.1071-09.2009.

30.

Omega-3 fatty acids and dementia.

Cole GM, Ma QL, Frautschy SA.

Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):213-21. doi: 10.1016/j.plefa.2009.05.015. Epub 2009 Jun 12. Review.

31.

Differential FDDNP PET patterns in nondemented middle-aged and older adults.

Ercoli LM, Siddarth P, Kepe V, Miller KJ, Huang SC, Cole GM, Lavretsky H, Bookheimer SY, Kim J, Phelps ME, Barrio JR, Small GW.

Am J Geriatr Psychiatry. 2009 May;17(5):397-406. doi: 10.1097/JGP.0b013e318198750b.

32.

Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid.

Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM.

Arch Neurol. 2009 Apr;66(4):448-57. doi: 10.1001/archneurol.2009.22.

33.

Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.

Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR.

Arch Gen Psychiatry. 2009 Jan;66(1):81-7. doi: 10.1001/archgenpsychiatry.2008.516.

34.

Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model.

Begum AN, Yang F, Teng E, Hu S, Jones MR, Rosario ER, Beech W, Hudspeth B, Ubeda OJ, Cole GM, Frautschy SA.

J Alzheimers Dis. 2008 Dec;15(4):625-40.

35.

GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.

Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA.

Neurobiol Dis. 2009 Feb;33(2):193-206. doi: 10.1016/j.nbd.2008.10.007. Epub 2008 Nov 5.

36.

Biochemical markers in persons with preclinical familial Alzheimer disease.

Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL.

Neurology. 2008 Jul 8;71(2):85-92. doi: 10.1212/01.wnl.0000303973.71803.81. Epub 2008 May 28.

PMID:
18509095
37.

Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes.

Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, Gylys KH.

Am J Pathol. 2008 Jun;172(6):1683-92. doi: 10.2353/ajpath.2008.070829. Epub 2008 May 8.

38.

Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease.

Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA.

J Pharmacol Exp Ther. 2008 Jul;326(1):196-208. doi: 10.1124/jpet.108.137455. Epub 2008 Apr 16.

39.

p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis.

Ma QL, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM.

J Biol Chem. 2008 May 16;283(20):14132-43. doi: 10.1074/jbc.M708034200. Epub 2008 Mar 17.

40.

Current and future uses of neuroimaging for cognitively impaired patients.

Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V, Barrio JR.

Lancet Neurol. 2008 Feb;7(2):161-72. doi: 10.1016/S1474-4422(08)70019-X. Review.

41.

Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention.

Ma QL, Teter B, Ubeda OJ, Morihara T, Dhoot D, Nyby MD, Tuck ML, Frautschy SA, Cole GM.

J Neurosci. 2007 Dec 26;27(52):14299-307.

42.

Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models.

Ma QL, Harris-White ME, Ubeda OJ, Simmons M, Beech W, Lim GP, Teter B, Frautschy SA, Cole GM.

J Neurochem. 2007 Nov;103(4):1594-607. Epub 2007 Aug 30.

43.

Neuroprotective effects of curcumin.

Cole GM, Teter B, Frautschy SA.

Adv Exp Med Biol. 2007;595:197-212. Review.

44.

PET of brain amyloid and tau in mild cognitive impairment.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR.

N Engl J Med. 2006 Dec 21;355(25):2652-63.

45.
46.

The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease.

Cole GM, Frautschy SA.

Exp Gerontol. 2007 Jan-Feb;42(1-2):10-21. Epub 2006 Oct 17. Review.

PMID:
17049785
47.

Commentary on "Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery." Pleiotropic approaches to Alzheimer's and other diseases of aging.

Cole GM, Frautschy SA.

Alzheimers Dement. 2006 Oct;2(4):284-6. doi: 10.1016/j.jalz.2006.08.006. No abstract available.

PMID:
19595901
48.

Cat and mouse.

Cole GM, Frautschy SA.

Neuron. 2006 Sep 21;51(6):671-2.

49.

Alzheimer's amyloid story finds its star.

Cole GM, Frautschy SA.

Trends Mol Med. 2006 Sep;12(9):395-6. Epub 2006 Aug 1.

PMID:
16880006
50.

Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease.

Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM.

Nat Neurosci. 2006 Feb;9(2):234-42. Epub 2006 Jan 15.

PMID:
16415866

Supplemental Content

Support Center